Market cap
$20,026 Mln
Recently Viewed
Clear AllMarket cap
$20,026 Mln
Revenue (TTM)
$3,247 Mln
P/E Ratio
--
P/B Ratio
8.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
411.6
Debt to Equity
1.1
Book Value
$12.7
EPS
$-1.1
Face value
--
Shares outstanding
190,888,211
CFO
$-634.25 Mln
EBITDA
$-2,561.19 Mln
Net Profit
$-3,070.41 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
EXACT Sciences Corporation (EXAS)
| 3.3 | 1.4 | 3.0 | 130.0 | 17.8 | -5.0 | 32.6 |
|
BSE Sensex*
| -6.4 | 6.4 | -3.5 | 0.9 | 10.0 | 10.7 | 11.9 |
|
S&P Midcap 400#
| 9.6 | 9.8 | 4.2 | 33.7 | 13.5 | 6.3 | 9.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
EXACT Sciences Corporation (EXAS)
| 80.7 | -23.9 | 49.4 | -36.4 | -41.3 | 43.3 | 46.6 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
EXACT Sciences Corporation (EXAS)
|
104.9 | 20,026.1 | 3,247.0 | -208.0 | -5.5 | -8.7 | -- | 8.3 |
| 310.9 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 | |
| 60.6 | 9,266.7 | 1,215.6 | 81.1 | 10.2 | 4.1 | 111.8 | 4.5 | |
| 185.5 | 9,073.0 | 4,015.4 | -144.3 | 9.9 | -4.4 | -- | 2.8 | |
| 142.8 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 176.8 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 | |
| 749.4 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 | |
| 573.4 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 | |
| 62.0 | 9,053.6 | 0.0 | -766.6 | -- | -25.6 | -- | 3.3 | |
| 439.2 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with... colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Read more
Chairman of The Board & CEO
Mr. Kevin T. Conroy
Chairman of The Board & CEO
Mr. Kevin T. Conroy
Headquarters
Madison, WI
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of EXACT Sciences Corporation (EXAS) is $104.91 (NASDAQ) as of 23-Mar-2026 09:30 EDT. EXACT Sciences Corporation (EXAS) has given a return of 17.8% in the last 3 years.
Since, TTM earnings of EXACT Sciences Corporation (EXAS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-92.67
|
8.03
|
|
2024
|
-10.12
|
4.33
|
|
2023
|
-65.68
|
4.26
|
|
2022
|
-14.10
|
2.89
|
|
2021
|
-22.53
|
3.96
|
The 52-week high and low of EXACT Sciences Corporation (EXAS) are Rs 1,895.38 and Rs 38.81 as of 21-Apr-2026.
EXACT Sciences Corporation (EXAS) has a market capitalisation of $ 20,026 Mln as on 17-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in EXACT Sciences Corporation (EXAS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.